13价肺炎球菌结合疫苗对中国儿童疫苗血清型社区获得性肺炎球菌病的有效性:一项检测阴性病例对照研究
该研究在苏州大学附属儿童医院对5岁以下呼吸道感染患儿开展检测阴性病例对照研究,纳入2018年1月至2020年12月2371株肺炎链球菌分离株。PCV13/非PCV13血清型对照研究中总体疫苗有效性(VE)为50.0%(95%CI:15.0,70.7),匹配的PCV13/肺炎链球菌阴性对照研究中VE为74.4%(95%CI:60.7,83.3);接种≥2剂或≥3剂的VE高于≥1剂,对血清型6B、6A和19F的VE高于其他血清型。
要点
- PCV13/非PCV13血清型对照研究中总体VE为50.0%(95%CI:15.0,70.7)。
- 匹配的PCV13/肺炎链球菌阴性对照研究中VE为74.4%(95%CI:60.7,83.3)。
- 接种≥2剂或≥3剂的VE高于≥1剂,对6B、6A和19F血清型VE较高。
核心结论
- PCV13接种对儿童疫苗血清型肺炎球菌病有效,尤其对血清型6B、6A和19F。
研究设计与样本
- 在苏州大学附属儿童医院(SCH)5岁以下呼吸道感染住院患儿中开展检测阴性病例对照研究,时间为2018年1月至2020年12月。
- 病例为分离株检测阳性且血清型属于PCV13覆盖血清型的儿童;对照包括非PCV13血清型肺炎链球菌阳性儿童和肺炎链球菌阴性儿童,阴性对照按性别、年龄和入院日期1:1匹配。
- 共纳入2371株肺炎链球菌分离株进行分析,其中75.0%(1779/2371)为PCV13覆盖血清型,1779名儿童归为病例,592名儿童为非PCV13血清型对照,另匹配1779名儿童为肺炎链球菌阴性对照。
- 疫苗有效性(VE)采用logistic回归模型计算,公式为(1-调整后比值比)*100%。
主要发现
- 总体而言,40例病例(2.3%)和148名对照(6.2%)接种过疫苗。
- PCV13/非PCV13血清型病例对照研究中总体VE为50.0%(95%CI:15.0,70.7)。
- 匹配的PCV13/肺炎链球菌阴性病例对照研究中VE为74.4%(95%CI:60.7,83.3),高于PCV13/非PCV13血清型研究。
- 接种≥2剂或≥3剂的VE高于≥1剂。
- 针对特定PCV13血清型(6B、6A和19F)的VE高于其他血清型。
关键数值与推荐
- 病例定义:分离株检测阳性且血清型属于PCV13覆盖血清型的儿童。
- 对照定义:非PCV13血清型肺炎链球菌阳性儿童,或肺炎链球菌阴性儿童(按性别、年龄和入院日期1:1匹配)。
- VE计算公式:(1-调整后比值比)*100%。
- PCV13/非PCV13血清型对照研究VE:50.0%(95%CI:15.0,70.7)。
- 匹配的PCV13/肺炎链球菌阴性对照研究VE:74.4%(95%CI:60.7,83.3)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: In 2016, China licensed 13-valent pneumococcal conjugate vaccine (PCV13) based on a study that demonstrated its immunogenicity is non-inferior to PCV7. However, the real-world effectiveness of PCV13 against vaccine-serotype pneumococcal diseases in China has limited evidence. METHODS: A test-negative case-control study was conducted among children under 5 years old admitted to the Children's Hospital of Soochow University (SCH) with respiratory tract infections from January 2018 to December 2020. Cases were defined as children from whom the isolates were tested positive for Streptococcus pneumoniae (S. pneumoniae) with serotypes included in PCV13. Two control groups were included, one represented children with isolates positive for S. pneumoniae of non-PCV13 serotypes and the other comprised children who tested negative for S. pneumoniae. The S. pneumoniae-negative controls were selected by matching them to the cases based on gender, age and admission date in a 1:1 ratio. Vaccine effectiveness (VE) was calculated using a logistic regression model as (1- adjusted odds ratio) * 100 %. RESULTS: A total of 2371 pneumococcal isolates were included in the analysis, of which 75.0 % (1779/2371) were covered by PCV13 serotypes. Consequently, these 1779 children were classified as cases, and 592 children were designated as non-PCV13 serotype controls. Another 1779 children were correspondingly recruited as S. pneumoniae-negative controls. Overall, 40 cases (2.3 %) and 148 controls (6.2 %) had received vaccination. The overall VE in the PCV13/non-PCV13 serotypes case-control study was 50.0 % (95 % CI: 15.0, 70.7), which was lower than the VE of 74.4 % (95 % CI: 60.7, 83.3) in the matched PCV13/S. pneumoniae-negative case-control study. VE was higher for ≥ 2 or ≥ 3 doses of vaccination compared to ≥ 1 dose. VE against specific PCV13 serotypes (6B, 6A and 19F) was higher than for other serotypes. CONCLUSIONS: PCV13 vaccination demonstrates effectiveness against vaccine-serotype pneumococcal diseases in children, particularly for serotypes 6B, 6A and 19F.
引用
- Xiaofei L, Yudan LI, Qinghui C, et al. Effectiveness of 13-valent pneumococcal conjugate vaccine against vaccine-serotype community acquired pneumococcal diseases among children in China: A test-negative case-control study. Vaccine. 2024. PMID: 38296700. doi:10.1016/j.vaccine.2024.01.068
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。